In conclusion, we demonstrate that sGC stimulation by riociguat ameliorates portal hypertension, reduces liver fibrosis and inhibits hepatic necroinflammation – especially in cholestatic cirrhosis. The gene discussed is SGCB; the disease is portal hypertension.